Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!
Stay up-to-date on ASX-listed Life Sciences stocks!
Make sure you subscribe to Stocks Down Under today
No credit card needed and the trial expires automatically.
If investing in resources stocks (particularly junior explorers) is too risky, another option is investing in metal exchanges. But is…
Investors have been excited about Leo Lithium (ASX:LLL) over the past year and so have we! We thought this was…